RG7625

Hoffmann-La Roche · Phase 1 active Small molecule

At a glance

Generic name	RG7625
Sponsor	Hoffmann-La Roche
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Investigate the Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Repeated Dosing of RO5459072 in Volunteers With Celiac Disease (PHASE1)
A Study of RG7625 in Healthy Volunteers (PHASE1)
A Multiple Ascending-Dose Study of RG7625 in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RG7625 CI brief — competitive landscape report
RG7625 updates RSS · CI watch RSS
Hoffmann-La Roche portfolio CI